Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

NCT02443805 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.

NCT NCT02443805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
Lead sponsor
Stallergenes Greer
Phase
Phase 3
Overall status
Completed
Start date
September 29, 2015
Completion date
June 25, 2018
Enrollment
1,607 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

house dust mite allergy, rhinitis, allergic, perennial